This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (59)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David Thompson, PhD; Gerry Oster, PhD

JAMA. 1996;275(17):1339-1341.

Abstract
Objective.
—To assess changes in concurrent use of products containing terfenadine and contraindicated macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) and imidazole antifungals (ketoconazole, itraconazole) following reports of serious drug-drug interactions and changes in product labeling.

Design.
—Retrospective review of computerized pharmacy claims.

Setting.
—A large health insurer in New England.

Patients.
—Health plan members with 1 or more paid pharmacy claims for products containing terfenadine between January 1990 and June 1994.

Main Outcome Measures.
—Among persons with paid claims for terfenadine in any given month, percentage with a prescription for any contraindicated drug that alternatively was dispensed on the same day as ("same-day dispensing") or had therapy days that overlapped those of ("overlapping use") a prescription for terfenadine.

Results.
—Concurrent use of terfenadine and contraindicated drugs declined over the study period. The rate of same-day dispensing declined by 84%, from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first 6 months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin.

Conclusions.
—Despite substantial declines following reports of serious drug-drug interactions and changes in product labeling, concurrent use of terfenadine and contraindicated macrolide antibiotics and imidazole antifungals continues to occur.

(JAMA. 1996;275:1339-1341)

Author Affiliations
From Policy Analysis Inc, Brookline, Mass.

Footnotes
Reprints: Gerry Oster, PhD, Policy Analysis Inc, 4 Davis Ct, Brookline, MA 02146.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Detection and reporting of drug-induced proarrhythmias: room for improvement
Darpo
Europace 2007;9:iv23-iv36.
ABSTRACT | FULL TEXT  

Incidence and Severity of Potential Drug-Dietary Supplement Interactions in Primary Care Patients: An Exploratory Study of 2 Outpatient Practices
Peng et al.
Arch Intern Med 2004;164:630-636.
ABSTRACT | FULL TEXT  

Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride
Barbey et al.
J CARDIOVASC PHARMACOL THER 2002;7:65-76.
ABSTRACT  

Coprescribing and Codispensing of Cisapride and Contraindicated Drugs
Jones et al.
JAMA 2001;286:1607-1609.
ABSTRACT | FULL TEXT  

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology
Haverkamp et al.
Eur Heart J 2000;21:1216-1231.
 

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology
Haverkamp et al.
Cardiovasc Res 2000;47:219-233.
FULL TEXT  

Impact of a Web-Based Clinical Information System on Cisapride Drug Interactions and Patient Safety
McMullin et al.
Arch Intern Med 1999;159:2077-2082.
ABSTRACT | FULL TEXT  

Use of Terfenadine and Contraindicated Drugs
Zechnich and Hedges
JAMA 1996;276:953-953.
ABSTRACT  

Use of Terfenadine and Contraindicated Drugs
Nader
JAMA 1996;276:953-953.
ABSTRACT